FGFR3 overexpression
|
Urothelial Cancer
|
FGFR3 overexpression
|
Urothelial Cancer
|
atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria
|
atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria
|
FGFR3 overexpression
|
Head and Neck Cancer
|
FGFR3 overexpression
|
Head and Neck Cancer
|
BAY 1163877 Sensitive: C3 – Early Trials
|
BAY 1163877 Sensitive: C3 – Early Trials
|
FGFR3 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
FGFR3 overexpression
|
Lung Non-Small Cell Squamous Cancer
|
BAY 1163877 Resistant: C3 – Early Trials
|
BAY 1163877 Resistant: C3 – Early Trials
|
FGFR3 overexpression
|
Bladder Cancer
|
FGFR3 overexpression
|
Bladder Cancer
|
TAS 120 Sensitive: D – Preclinical
|
TAS 120 Sensitive: D – Preclinical
|
FGFR3 overexpression
|
SCCHN
|
FGFR3 overexpression
|
SCCHN
|
BAY 1163877 Sensitive: D – Preclinical
|
BAY 1163877 Sensitive: D – Preclinical
|
FGFR3 overexpression
|
SCCHN
|
FGFR3 overexpression
|
SCCHN
|
infigratinib Sensitive: D – Preclinical
|
infigratinib Sensitive: D – Preclinical
|
FGFR3 overexpression
|
Breast Cancer
|
FGFR3 overexpression
|
Breast Cancer
|
FGFR inhibitor Sensitive: D – Preclinical
|
FGFR inhibitor Sensitive: D – Preclinical
|